Recent Updates
Recently added Catalysts
INAB Positive Sentiment

IN8bio to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

Monday, February 24, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: IN8bio, Inc. will have its CEO, William Ho, present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference on February 25, 2025. The company specializes in gamma-delta T cell therapies and is actively advancing its clinical programs, including INB-400 in a Phase 2 trial for glioblastoma. The presentation is expected to enhance the company's exposure in the biopharmaceutical sector and further engage potential investors.
Price reaction · baseline $8.145 (2025-02-21 close) · 1 other INAB headline(s) in the window, move may be shared
day 0 close
+0.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • IN8bio's CEO is presenting at a significant industry conference, showcasing leadership and visibility.
  • The company is focused on innovative gamma-delta T cell therapies, indicating a strong research and development strategy.
  • Their lead program, INB-400, is currently in a Phase 2 trial, demonstrating progress in clinical development.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+70%
120-day peak, hindsight
Typical move
5.4%
average across 6 past catalysts
Cash runway
~11 mo
Medium dilution risk
Lead asset
EAGD T-cell infusion
Phase 1 · Acute Myeloid Leukemia

Full Press Release Details

NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced that William Ho, CEO and co-founder, will be presenting at the:
H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference
Date/Time Tuesday, February 25, 2025, at 11:00 a.m. ET.
Webcast Link https://journey.ct.events/view/acb6057e-9d9b-427e-b490-eaf85a5c2910
A live webcast and replay will be available under "Events and Presentations" in the News & Presentations section of the IN8bio website at https://investors.in8bio.com.
IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The company’s lead program INB-400 is in a Phase 2 trial in GBM. Additional programs include Phase 1 trials in solid and hematologic tumors, including INB-200 for GBM and INB-100 for patients with hematologic malignancies undergoing transplantation. For more information about IN8bio, visit www.IN8bio.com.
Investor & Corporate Contact
Glenn Schulman, PharmD, MPH

Frequently Asked Questions

What is IN8bio focused on?

IN8bio specializes in innovative gamma-delta T cell therapies for cancer.

When will William Ho present at the conference?

William Ho will present on February 25, 2025, at 11:00 a.m. ET.

What is INB-400 in clinical trials for?

INB-400 is in a Phase 2 trial for glioblastoma (GBM).

Where can I access the live webcast?

The live webcast can be accessed on IN8bio's website under Events & Presentations.

What types of tumors are being targeted by IN8bio's programs?

IN8bio is targeting solid and hematologic tumors with its clinical programs.

ShareAdd on Google
Tags: INAB Viatris Investor Conferences Healthcare gamma-delta T cells H.C. Wainwright Phase 2 trial cancer immunotherapy
Last updated: Feb 24, 2025

Biotech snapshot

Cash runway
$18M liquidity · $2M/mo burn
~11 mo
Medium dilution risk
Lead asset
EAGD T-cell infusionPhase 1
Acute Myeloid Leukemia →

Catalyst track record

+70%
best trade around INAB's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for INAB.

See every catalyst's timing & PoA →